Single-dose rituximab to prevent EBV after kidney transplant
Treatments studied
Part of Infections clinical trials.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older at the time of your transplant
- You received a kidney transplant (and also a kidney-pancreas transplant at the same time)
- You were EBV-negative before transplant (blood tests: EBV marker tests are negative in the 6 months before through transplant day)
- Your donor kidney was EBV-positive
- You can take part in study visits and follow the plan, and you are not in another drug treatment study
- If you could become pregnant: you have a negative pregnancy test and will use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
Hear when a new Epstein-Barr Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.